According to Zacks, “We are disappointed with Henry Schein lowering the upper end of the previously provided EPS guidance range for 2016. Meanwhile, foreign currency fluctuations and competitive headwinds continue to impede the company’s business. However, on a positive note, Henry Schein’s impending acquisition of Marrodent should help it tap into the abundant dental market opportunities in Poland. We are also encouraged by the company’s recent strong share gains in both North American and overseas markets. Its recent investment in Custom Automated Prosthetics – a U.S. digital laboratory supply company offering CAD/CAM equipment and zirconia materials, buoys optimism. However, the company’s weakness in North American Dental sales was less than expectation. The year-over-year deterioration in Henry Schein’s gross margin figure on account of higher cost of sales also depresses us.”
A number of other research analysts have also recently weighed in on the stock. Robert W. Baird reaffirmed an outperform rating and issued a $176.00 price objective (up previously from $175.00) on shares of Henry Schein in a report on Tuesday, October 4th. Bank of America Corp. initiated coverage on shares of Henry Schein in a report on Monday, September 12th. They issued a buy rating and a $185.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $157.92.
Shares of Henry Schein (NASDAQ:HSIC) traded up 1.20% on Wednesday, hitting $163.71. 17,358 shares of the company were exchanged. Henry Schein has a 52-week low of $140.11 and a 52-week high of $183.00. The stock has a market capitalization of $13.39 billion, a PE ratio of 27.73 and a beta of 1.05. The firm’s 50-day moving average is $162.61 and its 200-day moving average is $170.46.
Henry Schein (NASDAQ:HSIC) last posted its earnings results on Thursday, August 4th. The company reported $1.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.01. The company earned $2.87 billion during the quarter, compared to the consensus estimate of $2.85 billion. Henry Schein had a net margin of 4.42% and a return on equity of 17.84%. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.46 earnings per share. Equities research analysts predict that Henry Schein will post $6.57 earnings per share for the current year.
In related news, Director Paul Brons sold 3,381 shares of the company’s stock in a transaction dated Monday, August 29th. The shares were sold at an average price of $164.03, for a total transaction of $554,585.43. Following the completion of the sale, the director now owns 13,715 shares of the company’s stock, valued at approximately $2,249,671.45. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.27% of the company’s stock.
A number of hedge funds have recently made changes to their positions in HSIC. Quadrant Capital Group LLC boosted its stake in shares of Henry Schein by 0.4% in the second quarter. Quadrant Capital Group LLC now owns 742 shares of the company’s stock valued at $128,000 after buying an additional 3 shares in the last quarter. Montag & Caldwell LLC boosted its stake in shares of Henry Schein by 0.3% in the second quarter. Montag & Caldwell LLC now owns 2,700 shares of the company’s stock valued at $477,000 after buying an additional 7 shares in the last quarter. Cleararc Capital Inc. boosted its stake in shares of Henry Schein by 0.9% in the second quarter. Cleararc Capital Inc. now owns 2,013 shares of the company’s stock valued at $356,000 after buying an additional 17 shares in the last quarter. Wetherby Asset Management Inc. boosted its stake in shares of Henry Schein by 0.6% in the second quarter. Wetherby Asset Management Inc. now owns 3,350 shares of the company’s stock valued at $592,000 after buying an additional 20 shares in the last quarter. Finally, Ranger Investment Management L.P. boosted its stake in shares of Henry Schein by 1.5% in the second quarter. Ranger Investment Management L.P. now owns 1,370 shares of the company’s stock valued at $242,000 after buying an additional 20 shares in the last quarter. 91.98% of the stock is owned by institutional investors.
Henry Schein Company Profile
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.